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 Introduction
   Lung cancer, a refractory cancer, is the most 
common cause of cancer-related deaths in Japan 
and developed Western nations, accounts for 
approximately 20% of overall cancer-related deaths, 
and has a low 5-year relative survival rate[NOTE 1] 
of approximately 30% (Figure 1).[1] This is due to 
the difficulty of early detection and lack of well-
established treatment methods that would enable a 
drastic improvement in the cure rate. Early detection 
combined with surgical treatment is the classic 
requirement for it to be cured. However, since lung 
cancer is often already inoperable and progressive by 
the time of its detection, up until now, its treatment has 
been no more than life extension and symptom relief. 
   With recent progress in molecular biology, the 
understanding of various disease mechanisms 
of humans at cellular and molecular levels has 
improved, resulting in a number of reports identifying 
molecules involved in the onset and progression 
of diseases. Accumulated knowledge on various 
biological molecules and mechanisms involved in 
the development and progression of cancer is being 
effectively used for the development of cancer 
treatments. In particular, in a recent achievement 
of research and development on molecular target 
therapy, treatment by blocking the function of targeted 
1
biological molecules involved in the abovementioned 
cancer, has been dramatic. It is hoped that molecular 
target therapy will become an effective method to 
treat refractory cancers such as progressive cancer 
and lung cancer, which are untreatable with traditional 
anticancer drugs, and that it will bring about 
personalized medicine, providing the best treatment 
for individual patients.[NOTE 2] 
   Here, I will introduce the trends in molecular target 
therapy, focusing on the treatment for lung cancer. 
First, I will discuss the importance of lung cancer 
treatment for Japanese and international healthcare 
from the epidemiological perspective. Then, I will 
introduce the status of molecular targeting treatment 
within overall cancer treatment as well as within 
lung cancer treatment. Finally I will exemplify the 
discovery and clinical application of therapeutic target 
gene EML4-ALK for lung cancer, discovered by Dr. 
Hiroyuki Mano of the University of Tokyo/Jichi 
Medical University, as a significant achievement of 
recent years. 
The importance of lung cancer 
treatment – an epidemiological 
perspective
   According to an estimation by the World Health 
Organization (WHO), in 2007, 7.9 million people died 
of cancer, representing approximately 13% of the total 
[NOTE 1] : 5-year relative survival rate
   The index of the proportion of people diagnosed with cancer who survive 5 years compared to the proportion 
of the Japanese population in general who are still alive in 5 years. The general Japanese population in this case 
indicates the Japanese population adjusted for the distribution of gender, birth year, and age. 
[NOTE 2] : Personalized medicine
   Treatment planning selecting for the most effective drugs, doses, and administration methods with the fewest 
side effects based on an investigation of an individual patient’s physical characteristics and its relationship to the 
disease based on genetic testing etc. Since molecular target therapy is provided based on information on genetic 
abnormalities and excessive expression of its products, it leads to personalized medicine (mentioned later in 3-2).
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deaths around the world and confirming cancer as a 
major cause of death worldwide. In particular, lung 
cancer  contributes to a signifi cant portion of cancer-
related deaths. The American Cancer Society’s (ACS) 
Global Cancer Facts & Figures 2007 estimated that 
approximately 975,000 males and 376,000 females 
died of lung cancer in 2007, and reported that lung 
cancer was the leading cause of death in men and 2nd 
leading cause of death in women among all cancer-
related deaths. 
   As for regional factors, according to the ACS, 
lung cancer is the most common cause of cancer-
related death in Central, North, and South Americas, 
European nations, and Australia. In addition, lung 
cancer is the most fatal cancer in Asia outside of the 
South and Central regions. Specifi cally, taking the U.S. 
as an example, the U.S. Centers for Disease Control 
and Prevention (CDC) reported that 89,243 males and 
69,356 females died of lung cancer in 2006. 
   Also in Japan, lung cancer is a significant cause 
of death. Since cancer replaced cerebral vascular 
diseases and cardiac diseases as the most common 
cause of death in 1981, the number of cancer-related 
death keeps increasing. Within these cancer-related 
deaths, lung cancer has been the most common since 
it replaced gastric cancer in 1998. In 2008, 342,963 
people died of cancer, within which, 66,849 people, 
19.5% of overall cancer-related deaths, died of lung 
cancer.[2] 
   Changes in the mortality rate, excluding the effect 
of age-distribution changes (the age-adjusted death 
rate[NOTE 3]), show that the overall death rate from 
cancer is decreasing in Japan. However, the death rate 
from lung cancer has remained constant (Figure 2). 
In addition, there is a gender difference in the death 
rate of lung cancer, which is higher in males by a 
magnitude of 3 to 4 times. 
   To summarize, since lung cancer causes a signifi cant 
Source: Cabinet Offi ce, the Second Life Innovation Task Force Data Collection[1] 
Figure 1 :  The number of cancer patients and the survival rate
[NOTE 3] : Age-adjusted death rate
   Death rate calculated with a standardized population to exclude the effects of the population’s age structure. In 
Japan, the “1985 model population” is often used as the standardized population. 
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number of deaths worldwide, the development of 
effective therapeutic methods to treat lung cancer 
would be beneficial to Japanese as well as global 
healthcare. 
Characteristics of molecular 
target therapy and its status within 
cancer treatment
3-1 Characteristics of molecular target therapy
   Molecular target therapy aims to improve 
symptoms and to heal the disease by suppressing 
specific molecules involved in the development 
and progression of the disease. It uses medication 
– molecular target drugs – designed or selected to 
suppress/ block the functions of specific molecules. 
Therefore, molecular target drugs are developed by 
targeting specifi c molecules based on the assumption 
that the suppression of those specific molecules will 
treat the disease. Target molecules of the drug can be 
a single molecule or a group of molecules with similar 
molecular structures, and the drugs targeting the latter 
are called multi-target drugs. 
   Molecular target drugs include low molecular drugs 
targeting molecules inside the cell, and antibody 
drugs targeting protein and/or sugar chains on the 
cell surface. These drugs are indicated for a wide 
range of diseases. For example, antibody drugs on 
the market or in post-phase III clinical trials have 
a variety of indications for autoimmune disease 
such as rheumatism, cancer and related diseases, 
cardiovascular diseases, infectious diseases, 
neurological diseases, asthma, and osteoporosis.[3]
3-2 Status within cancer treatment
   Cancer therapy consists of three major types of 
treatments: surgical and radiation therapy as a local 
treatment, chemotherapy as a systemic treatment, and 
a combination of these treatments, multi-modality 
therapy, is the common treatment of cancer clinically. 
In addition to these three major types of treatment, 
immunological therapy and gene therapy have been 
developing in recent years and their clinical application 
is progressing. Each therapy is selected based on the 
type of cancer (which organ is affected), the stage 
of cancer (cancer progression), and the histological 
type (pathological category of cancer), as well as the 
patient’s medical history and general status. Refer to 
the report on Science & Technology Trends by Dr. 
Shoji et al. for details on cancer treatment.[4]
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Produced by the STFC based on reference[2]
Figure 2 :  Transitions of Age-Adjusted Cancer Deaths in Japan
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   Many of traditional anticancer drugs are cytotoxic, 
and treatment that uses medication is termed 
chemotherapy. Molecular target therapy is categorized 
as chemotherapy for its use of medication. 
   Molecular target therapy for cancer uses molecular 
target drugs that suppress/ block the function of 
biological molecules involved in the pathogenesis, 
progress, and metastasis of cancer. Figure 3 shows 
candidate biological molecules that are the targets 
of cancer treatment.[5] Target molecules in cancer 
treatment varies widely, in other words, cancer 
pathogenesis and malignant alteration are induced by 
a complex molecular mechanism, which makes up 
the “character” of an individual cancer. Therefore, 
this treatment requires a diagnosis of this character to 
see if medication targeting specifi c molecules will be 
effective. To achieve this, patients need to be clinically 
screened for abnormalities in the biological molecules 
involved in cancer or in the genes coding these 
molecules before treatment is provided. Because of 
this, molecular target therapy is expected to progress 
into personalized medicine.  
   The status of molecular target therapy within cancer 
treatment becomes clearer when the side effects of 
molecular target drugs and traditional cytotoxic drugs 
are compared. General cytotoxic agents kill cancer 
cells by blocking DNA synthesis or cell division in 
cells with frequently repeated cell divisions. Since 
the drug attacks healthy cells as well as cancer cells, 
continuous treatment often becomes diffi cult due to a 
variety of side effects such as the loss of hair, nausea, 
vomiting, gastrointestinal tract disturbances, and 
hematotoxicity. However, since molecular target drugs 
only suppress/block the activity of specifi c molecules, 
it is believed that the side effects, like ones caused by 
cytotoxic drugs, can be reduced. However, the risk of 
new side effects have been reported with the progress 
of its clinical use. Gefitinib (Iressa®), a molecular 
target drug for lung cancer has been reported to have 
caused severe lung disorder (mentioned in 4-3).
Trends in molecular targeting 
treatment in lung cancer
   In this chapter, I will describe molecular target 
therapy specifi c to lung cancer. 
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Produced by the STFC based on reference[5]
Figure 3 :  Examples of therapeutic target molecules and molecular target drugs for cancer
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4-1 General Treatment Strategy for Lung Cancer 
   As with other cancer treatments, the basic direction 
of lung cancer treatment is selected based on the 
histological type and stage of cancer progression. 
In particular, the two histological types, small-cell 
lung cancer and non-small-cell lung cancer, have 
been important factors in the treatment protocol for 
lung cancer. Histological type can be determined 
by histopathological examination of expectorated 
sputum or cells obtained from the focus in the lung. 
Small-cell lung cancer is named after the small size 
of cancer cells compared to the cells of other types 
of lung cancer. Non-small-cell lung cancer indicates 
lung cancer other than small-cell lung cancer, and 
is further categorized to adenocarcinoma, which 
frequently occur in the peripheral of the lungs, 
squemous cell cancer, which frequently occurs near 
where bronchia enters the lungs and large-cell cancer, 
which proliferate rapidly resulting in a large cancer 
by the time of detection. The latter, non-small-cell 
lung cancer takes up 85~90% of total lung cancer in 
Japan. In addition to small-cell lung cancer and non-
small-cell lung cancer categorization, the stage of 
lung cancer is examined before selecting the treatment 
methods. 
   Treatment of lung cancer is indicated in Guidelines 
for Lung Cancer Treatment by EBM Methods, 2005 
Edition published by the Japan Lung Cancer Society,[6] 
an NPO. These guidelines indicate the principles of 
Evidence Based Medicine (EBM) and standard lung 
cancer treatment methods. The relationship between 
the histological type and the stage of lung cancer is 
indicated in Figure 4. Therefore, surgical treatment, 
radiotherapy, and chemotherapy are not set up on one-
on-one basis with each histology-stage relationship 
but rather, with multiple methods and multiple 
chemotherapy agents. 
   Currently, molecular target therapy is practiced only 
in non-small-cell lung cancer (Figure 4). The three 
molecular target drugs for lung cancer that have been 
approved in Japan have indications for inoperable 
(Stage III~IV in Figure 4) or recurrent non-small-
cell lung cancer. On the other hand, molecular target 
therapy is not practiced for small-cell lung cancer 
due to lack of effective molecular target drugs. For 
small-cell lung cancer, chemotherapy using traditional 
cytotoxic drugs and radiotherapy are used as effective 
methods.
Produced by the STFC based on reference[5]
Figure 4 :  The relationship between the histological type and stage of lung cancer indicated in Guidelines for 
Lung Cancer Diagnosis (excluding recurrence)
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4-2 Characteristics and Uses of Molecular target 
drugs for Lung Cancer
   Here, I will discuss molecular target therapy for non-
small-cell cancer, focusing on the characteristics and 
the uses of molecular target drugs used for general 
practice in Japan.
   There are three drugs for lung cancer treatment with 
sales approval in Japan; gefinitib (Iressa®), which 
was approved in Japan before any other countries in 
July 2002, erlotinib (Tarceva®), which was approved 
in October 2007 and bevacizumab (Avastin®) 
(approved in June 2010). Of these drugs, Iressa® and 
Tarceva® are low molecular drugs, and had been 
used to treat over 85,000 lung cancer patients by April 
2009 in Japan. Avastin® is an antibody drug which 
was approved for colon and rectal cancers in April 
2007, and its indication was subsequently expanded 
to include lung cancer in November 2009. All three 
drugs are used for non-small-cell lung cancers that 
are inoperable or recurrent. Of the three drugs, 
Iressa® received sales approval from the U.S. Food 
and Drug Administration in May 2003, however, its 
use for new patients was basically banned in June 
2007. On the other hand, in the EU, drug developer 
AstraZeneca of the UK had its application to the 
European Medicines Evaluation Agency (EMEA) for 
sales approval in January 2005 turned down, however, 
the company reapplied in May 2008, and EMEA 
approved it in July 2009. The reason behind this 
difference is that the clinical effi cacy of Iressa® was 
reported to vary greatly depending on the background 
of the patient, in regard to factors such as ethnicity 
and genetic information, in previous global studies 
(ISEL, INTEREST, IPASS etc). Clinical effi cacy here 
points to survival benefi t indexed by survival period 
and survival rate, response rate indicating the effect 
of reducing cancer, and the recurrence suppression 
effect measured by relapse-free survival period and 
recurrence rates. 
   Iressa® and Tarceva® are low molecular drugs 
targeting the receptors of epidermal growth factor 
(EGF), known as a cellular proliferation/growth factor 
(Figures 3 and 5). EGF receptors are transmembrane 
molecules (glycoprotein), and are a class of receptor 
tyrosine kinases (EGFR tyrosine kinase) which 
specifically phosphorylate residues of tyrosine, an 
amino acid. In some types of lung cancer, EGFR 
tyrosine kinase coding gene (EGFR gene) mutation 
is reported to cause abnormal activation of EGFR 
tyrosine kinase, and the abovementioned two drugs 
block the EGFR tyrosine kinase activity. 
   Abnormal activity of tyrosine kinase, including 
EGFR, is believed to be one of the causes of various 
cancers including lung cancer. Tyrosine kinases 
usually play a central role in the proliferation 
mechanism of normal cells, taking charge of 
the regulation of “growth/proliferation factor 
(extracellular cellular proliferation signals) -> tyrosine 
kinase -> activation of intracellular proliferation 
signal transmission” pathway (Figure 5). This 
pathway is suppressed when there is no stimulation 
by extracellular cellular proliferation signaling 
molecules, and is transiently activated only when 
there is stimulation by cellular proliferation signaling 
molecules. However, when the pathway becomes 
constantly active due to the disruption of the pathway 
regulation caused by amplification, mutation, and/or 
structural changes in the tyrosine kinase coding gene, 
there will be a continuous intracellular proliferation 
stimulus. Subsequently, this is believed to lead to 
unlimited cellular proliferation.
   Since tyrosine kinase is involved in the fundamental 
life-sustaining process, regulation of cell proliferation, 
there has been a concern that drugs blocking such 
molecules may produce some grave side effects. 
However, since cells of certain types of cancer caused 
by EGFR gene mutation including lung cancer are 
much more sensitive to tyrosine kinase blocking 
compared to normal cells, it has been shown that 
drugs blocking the molecules swiftly produce effects 
only on cancer cells. 
   From global clinical trials and clinical experience 
after marketing, Iressa’s® clinical effect for lung 
cancer is suggested to vary with the background of 
the patient, including factors such as ethnicity, gender, 
histological type of cancer and smoking history.[7] 
In detail, it is more effective in Asians compared to 
Caucasians, and more effective on adenocarcinoma 
out of all non-small-cell lung cancers, and also on 
females and non-smokers. It is also reported that 
clinical effi cacy is high on lung cancer patients with 
mutation of the EGFR gene, the gene coding EGFR 
tyrosine kinase, the target of Iressa®. EGFR gene 
mutation is found in many lung cancers in Asians, 
adenocarcinoma and lung cancer in non-smokers, 
which makes Iressa® effective. In clinical trials 
with Japanese lung cancer patients with EGFR gene 
mutation as the subjects, which were publicized in 
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June 2010, the clinical effects of Iressa® were shown 
to be significantly higher than those of standard 
chemotherapy using traditional cytotoxic drugs.[8] In this 
trial, clinical effi cacy was measured by a progression-
free survival period, which is the amount of time 
survived without progression. To sum up the report, 
EGFR gene mutation is perceived as a prediction 
factor for the treatment effi cacy of Iressa®. Therefore, 
it is useful to check the presence of EGFR gene 
mutation before initiating treatment with the drug, 
and only those with such mutation should be treated. 
EGFR gene mutation screening was approved for 
coverage by insurance in June 2007 in Japan, and 
it is clinically practiced as a bench mark to judge 
an indication for Iressa®. To check the presence of 
EGFR gene mutation, various methods are being 
developed based on the direct sequence method and 
PCR (polymerase chain reaction). In addition, the 
sensitivity/specificity differences and equivalence 
among the checking methods are currently being 
examined.[7]
   Since Tarceva® targets EGFR tyrosine kinase, its 
mechanism of efficacy is believed to be similar to 
that of Iressa®. However, it is different from Iressa® 
in that it was shown to have a survival benefit for 
non-small-cell lung cancer patients in clinical trials 
abroad. The clinical effects of Tarceva®, similar to 
Iressa®, are higher in lung cancer in Asians, lung 
adenocarcinoma, lung cancer in non-smokers, and 
lung cancer patients with EGFR gene mutation, 
however, there is a report claiming that EGFR gene 
mutation and clinical effect do not correlate. In 
addition, there is a report that Tarceva® is clinically 
effective for lung cancer with histological type other 
than adenocarcinomma, lung cancer of smokers, and 
lung cancer patients without EGFR gene mutation. 
The difference in clinical effects between Tarceva® 
and Iressa® as well as criteria for the use of Tarceva® 
will be clarifi ed by the vigorous clinical trials which 
are currently underway. 
   Avastin® is an antibody drug (human monoclonal 
antibody) targeting vascular endothelial growth 
factor (VEGF). VEGF is a glycoprotein involved 
in vascularization, which is a critical process for 
cancer growth and metastasis. VEGF expression 
increases in various types of cancer including 
lung cancer and colon cancer, and the correlation 
between its expression and stages and prognosis of 
cancer has been reported. Avastin® was approved 
in the U.S. in February 2004 and in the EU in 
January 2005 for treating colon cancer as the 
first vascularization blocker in the world, and its 
indication was expanded to lung cancer in the U.S. 
and the EU as well as in Japan. It is approved for 
breast cancer and kidney cancer in the U.S. and the 
EU. Domestic clinical trials as well as those abroad 
with lung cancer patients as their subjects showed 
that the combination of Avastin® and CP therapy, 
a combination of carboplatin and paclitaxel used in 
standard chemotherapy, was affective in both Asian 
and western lung cancer patients.
 
4-3 Side Effects of and Drug Resistance to 
Molecular target drugs for Lung Cancer 
   As much as the clinical effectiveness of molecular 
target drugs such as Iressa® in treating lung cancer 
has been shown, there are still concerns about the risk 
of new side effects not seen with traditional cytotoxic 
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Figure 5 :  Effective mechanisms of molecular target drugs for lung cancer, Iressa® and 
Tarceva®
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anticancer drugs and about drug resistance.
   As for side effects, there have been reports of death 
caused by acute lung injury and interstitial pneumonia 
with the use of Iressa®. With consideration to the risk 
of such side effects and the clinical effects of the drug 
on lung cancer patients with EGFR gene mutation 
shown in 4-2, the Japan Lung Cancer Society has 
published its Guidelines on Gefi nitib Use (revised on 
July 25, 2005) to increase the benefi t/risk ratio. At the 
same time, death caused by interstitial pneumonia 
has been reported with the use of Tarceva®. 
Avastin® carries the risk of lung bleeding, and thus 
is contraindicated for use on patients with squamous 
epithelial lung cancer and on patients with a history of 
hemoptysis. 
   As for resistance to the drugs, patients clinically 
suited for Iressa® and Tarceva® acquire resistance 
within a year to a few years and the cancer recurs in 
almost all cases.[9] Additional EGFR gene mutation 
has been proposed to lower the drug binding to EGFR 
tyrosine kinase leading to the drug resistance, and 
investigation on the detailed mechanisms and drug 
development to overcome the resistance are underway. 
New Molecular Target Therapy for 
Lung Cancer
-The discovery of the EML4-
ALK fusion gene and its clinical 
application-
   The efficacy of molecular target drug Iressa®, 
which blocks the activity of EGFR tyrosine kinase in 
lung cancer patients with EGFR gene mutation, was 
introduced in the last chapter. This effi cacy indicates 
that the identification of the molecules causing lung 
cancer and drugs interfering with the activity of the 
molecule will result in an effective molecular target 
therapy. However, as discussed in 3-2, target molecules 
for cancer treatment vary widely, and there have been 
a great efforts in basic research inside and outside of 
the country, such as the search for and analysis of new 
target molecules in lung cancer treatment. Here, I will 
introduce a significant achievement in recent years, 
the discovery of EML4-ALK, a therapeutic target gene, 
by Dr. Hiroyuki Mano of the University of Tokyo/
Jichi Medical University and its clinical application as 
molecular target therapy.
5-1 The Discovery of a Therapeutic Target Gene 
-EML4-ALK Fusion Gene-  
   To discover a new oncogene causing lung cancer, 
Dr. Mano et al. started with uniquely upgrading and 
developing the method for screening oncogenes from 
patients’ specimens. This method makes almost all 
genes contained in a patient’s specimen to be forcibly 
expressed inside fibroblast cells using retrovirus 
vector (Figure 6). The isolation of oncogene from the 
transformed focus, in other words, focus formation 
assay, was one of the methods dominating medical 
research in the 1980s, however, organ specific 
oncogenes, expressed only in a specifi c organ, could 
not be isolated at the time. In order to achieve this, Dr. 
Mano et al. established a method to screen oncogenes 
by forcibly expressing almost all of the genes 
contained in a patient’s specimen based on a report 
by Dr. Moriuchi and his colleagues[10] at Nagasaki 
University, and reported this in 2007.[11]
   Using this gene screening method, Dr. Mano et al. 
discovered a new oncogene, a candidate for therapeutic 
target, the EML4-ALK fusion gene, from the specimen 
of the non-small-cell lung cancer (adenocarcinoma) 
of a 62-year old smoker, and reported it in Nature on 
August 2, 2007.[12] The ALK gene codes for a tyrosine 
kinase named anaplastic lymphoma kinase (ALK), 
and the EML4 gene codes for microtubule associated 
protein EML4, and normally, their products, ALK 
tyrosine kinase and EML4 protein, are present 
independently inside normal cells. However, when 
the ALK gene and the EML4 gene fuse, abnormally 
active EML4-ALK tyrosine kinase is produced by 
the EML4-ALK fusion gene (Figure 7) and is believed 
to cause lung cancer. In fact, EML4-ALK fusion gene 
has been shown to be present only in lung cancer 
cells. Please refer to the reference[12] as well as open 
patent information from Japan and the U.S. (Japanese 
Published Unexamined Application No.2008-295444, 
U.S. Patent application publication No.2009/099193 
etc) for details of EML4-ALK fusion gene.
   Lung cancer caused by EML4-ALK tyrosine kinase 
has been confirmed in animal studies. In transgenic 
mice with the EML4-ALK fusion gene expressed 
specifi cally in alveolar epithelium, making the lungs 
produce EML4-ALK tyrosine kinase, and developed 
a few hundred lung adenocarcinoma simultaneously 
in both lungs within a few weeks after birth.[13] The 
abnormal activity of tyrosine kinase had been already 
known to be carcinogenic in the case of EGFR (refer 
5
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to 4-2), and EML4-ALK tyrosine kinase further 
confi rmed it.  
   In normal human cells, since the ALK gene and 
the EML4 gene are located close to each other on 
chromosome 2 in opposite orientations, fusion of 
these genes observed in lung cancer cells indicates 
a structural abnormality of the chromosome. Using 
the genomic DNA of lung cancer patients, Dr. Mano 
et al revealed that the chromosome sandwiched 
between ALK gene and EML4 gene gets excised and 
subsequently the ALK gene and the EML4 gene are 
bound in revered orientation and become fused. 
   Examples of cancer caused by abnormally active 
tyrosine kinase production triggered by its gene 
fusing with another gene due to chromosomal 
structural abnormality are hematological cancers 
such as chronic myelocytic leukemia and anaplastic 
large cell lymphoma. Chronic myelocytic leukemia 
is believed to be caused by production of abnormally 
activated BCR-ABL tyrosine kinase due to an 
Abelson leukemia tyrosine kinase coding gene, the 
ABL gene, fusing with the BCR gene at the breakpoint 
cluster region (the BCR-ABL fusion gene) triggered by 
the structural abnormality of the chromosome. This 
structural abnormality in the chromosome is called 
Philadelphia chromosome. Currently, low molecular 
drug imanitib (Glivec®), which blocks abnormally 
activated BCR-ABL tyrosine kinase, is used as a 
first-line therapy in chronic myelocytic leukemia. In 
addition, anaplastic large cell lymphoma is believed to 
be caused by the production of abnormally activated 
NPM-ALK tyrosine kinase due to abovementioned 
ALK gene fusing with the nucleophosmin-anaplastic 
lymphoma kinase (NPM) coding NPM gene, triggered 
by a chromosomal structural abnormality. 
   On the other hand, fusion of genes caused by 
chromosomal abnormality was generally believed to 
cause hematological cancers, but not solid cancers 
such as lung cancer. Dr. Mitelman et al. reported in 
2004 that there was a possibility that chromosomal 
structural abnormality maybe a major cause of solid 
cancer,[14] however, it was not until the reports by 
Dr. Mano et al. in 2007 on lung cancer[12] and by 
Dr. Tomlin et al. on prostate cancer[15] that this was 
verified. The discovery of fusion gene EML4-ALK, 
which caused lung cancer, had a great academic 
impact, and was selected as one of 10 most important 
medical discoveries of the year in the December 2007 
issue of Nature Medicine.
   There are two important matters of clinical 
significance regarding the discovery of EML4-ALK 
fusion gene. One of them is the implementation of 
early lung cancer detection and the other is a potential 
for new molecular target drug development for lung 
cancer. Diagnosis and drug development are discussed 
below.  
5-2 Development and Clinical Application of New 
Lung Cancer Diagnostic Methods
   As mentioned in 4-1, lung cancer has been 
traditionally diagnosed based on pathohistological 
testing using specimens such as expectorated sputum. 
However, the sensitivity of such examinations is low. 
For example, expectorated sputum has to contain at 
least a few percent of cancer cells in 1ml of sample 
for a diagnosis. This means that in many cases, lung 
cancer has already progressed by the time of its 
diagnosis, and a method for detecting lung cancer with 
a higher level of sensitivity was long been awaited.
   Dr. Mano et al. have developed a molecular diagnostic 
method for lung cancer using reverse transcription 
polymerase chain reaction (RT-PCR).[12] This method 
detects the mRNA of EML4-ALK fusion gene which 
is only present in lung cancer cells. Its sensitivity is 
much higher than the traditional sputum examination, 
and it is able to detect lung cancer with only 10 cancer 
cells within 1ml of sputum sample. 
   In March 2009, Dr. Mano et al. founded the ALK 
Lung Cancer Study Group (ALCAS) in order to 
develop a nation-wide diagnostic network structure 
for lung cancer patients in Japan. ALCAS is carrying 
forward the abovementioned multiplex RT-PCR 
with improved sensitivity for EML4-ALK mRNA 
detection[16] as well as the intercalating antibody-
enhanced polymer method (iAEP method), which 
detects abnormally activated EML4-ALK tyrosine 
kinase with a high sensitivity[17] as a lung cancer 
diagnostic screening. Multiplex RT-PCR is an 
exhaustive detection method able to detect even the 
mRNA of EML4-ALK fusion genes variants, enabling 
early detection of lung cancer from samples such as 
pleural effusion, bronchial lavage fluid, and frozen 
specimen as well as sputum. 
   ALCAS has investigated the presence of the EML4-
ALK fusion gene in 220 patients with non-small-cell 
lung cancer using multiplex RT-PCR. As a result, the 
EML4-ALK fusion gene was detected in 11 patients, all 
of whom had adenocarcinoma, accounting for 5% of 
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the subjects of non-small-cell lung cancer. In addition, 
the detection rate of the EML4-ALK fusion gene was 
higher in patients with non-small-cell lung cancer 
below the age of 50, accounting for 35% of the total.[18] 
Meta-analysis of research data obtained inside and 
outside the country up to date, including past research 
done by Dr. Mano et al., showed that the EML4-ALK 
fusion gene was present in 3% to 7% of non-small-cell 
lung cancer in Asians (Japanese, Korean, Chinese).[19] 
As mentioned before, approximately 63,000 Japanese 
patients die from lung cancer annually, 85% to 90% 
of which are from non-small-cell lung cancer, and 
early detection of 5% of these patients and provision 
of molecular target therapy would save over 2500 
patients annually, thus its clinical value is extremely 
high. In particular, the diagnosis of patients with non-
small-cell lung cancer who are under the age of 50 is 
significant considering the high detection rate of the 
EML4-ALK fusion gene in this age group. 
   In addition, it is shown that patients with the EML4-
ALK fusion gene and those with EGFR gene mutation 
do not overlap.[12] In other words, EGFR gene mutation 
Produced by the STFC based on the lecture by Dr. Mano
Figure 6 :  Method of oncogene screening from patient specimen independently improved 
and developed by Dr. Mano and et al.
Produced by the STFC based on the lecture by Dr. Mano
Figure 7 :  Structure of EML4-ALK tyrosine kinase produced by EML4-ALK fusion gene
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and the EML4-ALK fusion gene have a mutually 
exclusive relationship. Therefore, it is necessary to 
conduct testing to detect the presence of EGFR gene 
mutation and the EML4-ALK fusion gene before 
starting a molecular target therapy, in order to judge 
the appropriate indication for Iressa®, Tarceva®, and 
ALK inhibitors shown in 5-3. 
5-3 Development of New Drugs for Lung Cancer
   Molecular target drugs for lung cancer, Iressa® 
and Tarceva®, and Glivec® for chronic myelocytic 
leukemia all block abnormally activated tyrosine 
kinase. This means that blocking the central cause 
of carcinogenesis, abnormal tyrosine kinase, is at the 
basis of its effective molecular targeting treatment. 
Therefore, EML4-ALK tyrosine kinase that has been 
abnormally activated by the fusion of ALK tyrosine 
kinase and EML4 protein can be a therapeutic target 
molecule. 
   Dr. Mano et al. reported, in December 2008, that 
EML4-ALK tyrosine kinase could be a possible 
candidate as a therapeutic target molecule for lung 
cancer treatment.[13] Transgenic mice expressing 
EML4-ALK tyrosine kinase specifi cally on the lung 
alveolar epithelium develop severe lung cancer. When 
2,4-pyrimidinediamide, a ALK tyrosine kinase 
specific blocker, was administered orally to these 
mice, most of the cancer disappeared within 25 days. 
Lung cancer caused by EML4-ALK tyrosine kinase 
was experimentally verifi ed to be treatable by specifi c 
inhibition of ALK tyrosine kinase.
   Taking the above experimental results, molecular 
target drug inhibiting ALK tyrosine kinase was 
developed and is currently undergoing clinical trials. 
Among the drugs being developed by multiple 
companies, crizotinib (code name: PF-02341066) 
developed by Pfi zer Inc. is at the forefront of clinical 
trials. Crizotinib is a multi target drug (refer to 3-1) 
which targets the molecules ALK tyrosine kinase 
and c-Met. c-Met is a receptor for hepatocyte growth 
factor (HGF), and is also a tyrosine kinase like ALK. 
In the phase I of clinical trials conducted in the U.S., 
Australia, and Korea in 2008, tests were conducted on 
various types of cancer, but subsequently, expansion 
tests were conducted in the same countries with 
non-small-cell lung cancer as the subject at the 
recommended dose achieved in the phase I of the 
clinical trials. 
   At the American Society for Clinical Oncology 
2010 conference held June 4 to 8, 2010, the results of 
clinical trials of crizotinib which had as its subjects 82 
patients with non-small-cell lung cancer with EML4-
ALK fusion gene in the U.S., Australia, and Korea 
were presented. Disease control rate of crizotinib 
was reported to be extremely high at 87%, adding 
together complete response (the drug was completely 
responded to), partial response (the drug was effective) 
and no change (the drug blocked the progression).[20] 
Reference[20] is the abstract of the presentation, and the 
actual presentation included additional patients and 
revised data.
   Global Phase III of clinical trials has already 
started for crizotinib (scheduled for September 2009 
to September 2012).[21] This Phase III of the clinical 
trials is aiming to evaluate the efficacy and safety 
of crizotinib by comparing the drug with standard 
chemotherapy agents (cytopathic drug pemetrexed or 
docetaxel). Countries conducting trials are the U.S., 
Australia, Bulgaria, Canada, Germany, Hong Kong, 
Hungary, Italy, Japan, Korea, Poland, Russia, Spain, 
and England, and within Japan, trials is scheduled 
to be conducted in Tokyo, Osaka, Aichi, Chiba, 
Hokkaido, Hyogo, Shizuoka, Okayama, and Fukuoka 
(as of July 10, 2010). 
Future Research and Development 
in Japan and Around the World
   Development of molecular target therapy for 
lung cancer started with the low molecular drug 
Iressa® targeting EGFR. Another low molecular 
drug targeting EGFR, Tarceva® and antibody drug 
Avastin® targeting VEGF are now used for lung 
cancer treatment. In addition, while the development 
of new molecular target drugs for lung cancer has 
undertaken, ALK tyrosine kinase inhibitor, which is 
currently undergoing clinical trials, should begin to 
be used in clinical practice in the near future. Though 
problems seen with Iressa® such as side effects and 
drug resistance should be resolved in the early stages, 
clinical selection of molecular target drugs for lung 
cancer is widening. 
   While the actual application of molecular target 
drugs for lung cancer is progressing, researchers 
around the world are making a great effort to find 
new target molecules and develop molecular target 
drugs. In the search of therapeutic target molecule 
for lung cancer, the Cancer Genome Atlas Project 
6
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(TCGA project), which started as a pilot project at the 
U.S. National Institutes of Health (NIH) in 2005, is 
receiving much attention. This project aims to identify 
the important genes responsible for lung cancer by 
screening the entire genome of cancer cells using 
squamous cell cancer of non-small-cell lung cancers 
and by evaluating the samples from patients (in their 
pilot project, they were targeting only 3 types of 
cancers: brain cancer, ovarian cancer, and lung cancer; 
however, the NIH reported that it would expand the 
targets to cover over 20 types of cancer in 2009). 
   While discovery of new therapeutic target molecules 
is anticipated from large-scale cancer genome 
analysis such as the TCGA project and currently 
ongoing projects, there has been an effort to expand 
the indication of molecular target drugs approved for 
treating other types of cancers to include lung cancer. 
Since there is an expansive range of basic and applied 
research as well as clinical trials, I have discussed the 
research by Dr. Mano et al. as a successful example. 
Dr. Mano et al. discovered the EML4-ALK fusion 
gene responsible for lung cancer by a focus formation 
assay, achieved by breaking through its limitations to 
isolate an organ-specifi c oncogenes. It is believed that 
this new technology will be extremely useful in the 
search for other oncogenes other than the EMK4-ALK 
fusion gene. The acceleration project, New Cancer 
Gene Identification Project by the Japan Science 
and Technology Agency (JST)’s Core Research for 
Evolutional Science and Technology (CREST) will use 
the methods developed by Dr. Mano et al. (scheduled 
for January 2009~March 2014).[22]
   In order for molecular target therapy for lung 
cancer to progress, it is urgent for the mechanisms 
and risks of side effects of and drug resistance 
to currently used drugs to be analyzed and for 
preventative measures for the risk to be developed. In 
addition, continuous efforts should be made to find 
new therapeutic molecules for lung cancer and to 
develop drugs and diagnostic methods based on the 
molecular information. In addition to these scientifi c 
and technological tasks, issues of the medical system 
should be resolved as well. Taking the research of Dr. 
Mano et al. as an example, since its clinical value has 
already been accepted, molecular diagnosis using 
the EML4-ALK fusion gene should be made more 
clinically accessible by opening it up to insurance 
coverage like EGFR gene testing. Early discovery of 
cancer by EML4-ALK fusion gene diagnosis enables 
the early start of treatment, which subsequently 
reduces treatment costs. In addition, in such cases, the 
indication of molecular target theraphy should be set 
earlier than stage III to IV of lung cancer. Guidelines 
on lung cancer treatment should be reconstructed, and 
physicians should be clearly notifi ed. 
   Cancer research in Japan has been conducted 
centering on the Comprehensive 10-year Strategy 
for Cancer Control (fiscal years 1984 to 1993), the 
New Comprehensive 10-year Strategy for Cancer 
Control (fiscal years 1994 to 2003), and the Third 
Comprehensive 10-year Strategy for Cancer Control 
(fiscal years 2004 to 2013).[23] From fiscal year 2011, 
cancer research is likely to progress even further with 
the general governmental action plan for science and 
technology policies. To achieve “life innovation,” 
the important goal set by the New Growth Strategy 
(cabinet approved on June 18, 2010), the action plan 
aims to actualize a “physically and mentally healthy 
and vigorous” society and “independence for the 
elderly and handicapped” by 2020, and promotes three 
priority tasks.[24] One of the three is the “improvement 
of the cure rate” of cancer “through innovative 
development of diagnosis and treatment,” and one 
of the directions to achieve this is the development 
of molecular target therapy. The development 
includes basic research such as “finding new targets 
by revealing the properties of cancer (proliferative 
inhibition, differentiation control, prevention of 
metastasis and cell death),” and extends to applied 
research as “research and development of drugs (low-
molecular and antibody drugs),” showing that the 
development of molecular target theraphy will be 
promoted as a national strategy. 
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